Post author: Gilda Tachedjian. Last update: 02/11/2015 at 12:08 pm by Gilda Tachedjian.
The Antiviral Screening Facility has the capacity to test chemical agents for their ability to inhibit the replication of HIV and herpes simplex (HSV) type 1 and 2 viruses in cell culture based assays and to elucidate their mechanism of action. This means that researchers can accelerate the development of new methods that may lead to better treatments for these chronic infections. The team has extensive experience in basic research and in particular in understanding the biology of retroviruses. All work undertaken by the facility is guided by principles outlined in the FDA guidelines for Antiviral Product Development.
The Burnet Antiviral Screening Facility can perform the following:
- Screen compounds for activity against a laboratory strain of human immunodeficiency virus type 1 (HIV-1) in cell culture based assays including determination of selectivity index (SI) of compounds (SI= 50% effective concentration/ 50% cytotoxic concentration)
- Evaluate activity of compounds against different HIV strains including distinct HIV subtypes and clinical isolates in cell lines and in primary cells.
- Test agents for ability to inhibit HIV strains resistant to drugs used in the clinic
- Evaluate mechanism of action of HIV inhibitors
- Select and characterise drug-resistant strains of HIV
- Evaluate antiviral activity in cell culture based assays in the presence of serum, seminal plasma, cervicovaginal secretions.
- Screen compounds for activity against HSV-1 and HSV-2 in cell culture assays including determination of selectivity index (SI) of compounds
Type: Research laboratory
Discipline areas: Biological Science
Precinct: Central, South east
Affiliations: Burnet Institute
Biological Science categories: Discovery, Drug development, High-throughput screening